The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. (BD) ...

BD (NYSE: BDX) announced that it reached an agreement with the SEC to resolve an investigation related to its Alaris system.

Fresenius Kabi is asking hospitals to remove certain pumps because of the risk of an alarm that could interrupt treatment.

Some of the key market players operating in the implantable infusion pump market include Medtronic, Flowonix Medical, Intera Oncology, Tandem Diabetes Care, United Therapeutics, ICU Medical, Johnson & ...

The SEC reached a settlement with Becton Dickinson over allegations of misleading investors regarding risks tied to its Alaris infusion pump. The company agreed to a $175 million civil penalty without ...

The FDA said Fresenius Kabi told customers to remove its Ivenix large-volume infusion pumps from use for repair.